A Multi-Criteria Decision Framework to Guide Treatment Decision-Making in Patients with Lenalidomide-Refractory Multiple Myeloma Post-DRd

This publication was supported by Stemline Therapeutics Switzerland GmbH.

It is based on a abstract presented at the European Hematology Association (EHA) Congress, held from the 12th–15th June 2025.